Design Therapeutics, Inc.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Pratik Shah Ph.D.

Employees

55

Headquarters

Carlsbad, CA, United States

Website

www.designtx.com